▶ 調査レポート

脂質降下薬(LLD)の世界市場2023-2031:産業分析、規模、シェア、成長、動向、予測

• 英文タイトル:Lipid-lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031

Transparency Market Researchが調査・発行した産業分析レポートです。脂質降下薬(LLD)の世界市場2023-2031:産業分析、規模、シェア、成長、動向、予測 / Lipid-lowering Drugs Market (Drug Class: Statins & Combination, PCSK9 Inhibitors, Bile Acid Sequestrants, Fibrates, Cholesterol Absorption Inhibitors, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031 / MRC2305A056資料のイメージです。• レポートコード:MRC2305A056
• 出版社/出版日:Transparency Market Research / 2023年3月24日
• レポート形態:英文、PDF、164ページ
• 納品方法:Eメール
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社の当調査レポートによると、世界の脂質降下薬(LLD)市場規模が、2023年の314億ドルから2031年に425億ドルとなり、予測期間中に年平均3.4%で成長すると推測されています。本レポートは、脂質降下薬(LLD)の世界市場について徹底的に分析・調査を行い、序論、仮定・調査手法、エグゼクティブサマリー、市場概要、主要インサイト、薬剤クラス別(スタチン・化合物、PCSK9阻害剤、胆汁酸封鎖剤、フィブラート、その他)分析、疾患別(高コレステロール血症、冠動脈疾患、高トリグリセリド血症)分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局)分析、地域別(北米、ヨーロッパ、アジア太平洋、中南米、中東・アフリカ)分析、競争状況など、以下の項目を整理しています。また、Sanofi、Pfizer, Inc.、GlaxoSmithKline plc、Novartis AG、Merck & Co., Inc.、Amgen Inc.、Takeda Pharmaceutical Company Limited、Sun Pharmaceutical Industries Ltd.、AbbVie, Inc.、Viatris (Mylan N.V.)、AstraZeneca PLC、Dr. Reddy’s Laboratories Ltd.など、主要企業情報を含んでいます。
・序論
・仮定・調査手法
・エグゼクティブサマリー
・市場概要
・主要インサイト
・世界の脂質降下薬(LLD)市場規模:薬剤クラス別
- スタチン・化合物の市場規模
- PCSK9阻害剤の市場規模
- 胆汁酸封鎖剤の市場規模
- フィブラートの市場規模
- その他薬剤クラスの市場規模
・世界の脂質降下薬(LLD)市場規模:疾患別
- 高コレステロール血症における市場規模
- 冠動脈疾患における市場規模
- 高トリグリセリド血症における市場規模
・世界の脂質降下薬(LLD)市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
・世界の脂質降下薬(LLD)市場規模:地域別
- 北米の脂質降下薬(LLD)市場規模
- ヨーロッパの脂質降下薬(LLD)市場規模
- アジア太平洋の脂質降下薬(LLD)市場規模
- 中南米の脂質降下薬(LLD)市場規模
- 中東・アフリカの脂質降下薬(LLD)市場規模
・競争状況

Lipid-lowering Drugs Market – Scope of Report
TMR’s report on the global lipid-lowering drugs market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global lipid-lowering drugs market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global lipid-lowering drugs market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the lipid-lowering drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global lipid-lowering drugs market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global lipid-lowering drugs market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global lipid-lowering drugs market.

The report delves into the competitive landscape of the global lipid-lowering drugs market. Key players operating in the global lipid-lowering drugs market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global lipid-lowering drugs market profiled in this report.

Key Questions Answered in Global Lipid-lowering Drugs Market Report
• What is the sales/revenue generated by lipid-lowering drugs across all regions during the forecast period?
• What are the opportunities in the global lipid-lowering drugs market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Lipid-lowering Drugs Market – Research Objectives and Research Approach
The comprehensive report on the global lipid-lowering drugs market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global lipid-lowering drugs market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global lipid-lowering drugs market.

レポート目次

1. Preface
    1.1. Market Definition and Scope
    1.2. Market Segmentation
    1.3. Key Research Objectives
    1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Lipid-lowering Drugs Market
4. Market Overview
    4.1. Introduction
        4.1.1. Segment Definition
    4.2. Overview
    4.3. Market Dynamics
        4.3.1. Drivers
        4.3.2. Restraints
        4.3.3. Opportunities
    4.4. Global Lipid-lowering Drugs Market Analysis and Forecast, 2017-2031
        4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
    5.1. Drug Pipeline Analysis
    5.2. COVID-19 Pandemic Impact on Industry (Value Chain and Short / Mid / Long Term Impact)
    5.3. Regulatory Scenario by Region/globally
    5.4. Patent Analysis
6. Global Lipid-lowering Drugs Market Analysis and Forecast, by Drug Class
    6.1. Introduction & Definition
    6.2. Key Findings / Developments
    6.3. Market Value Forecast, by Drug Class, 2017-2031
        6.3.1. Statins & Combination
        6.3.2. PCSK9 Inhibitors
        6.3.3. Bile Acid Sequestrants
        6.3.4. Fibrates
        6.3.5. Cholesterol Absorption Inhibitors
        6.3.6. Others
    6.4. Market Attractiveness, by Drug Class
7. Global Lipid-lowering Drugs Market Analysis and Forecast, by Indication
    7.1. Introduction & Definition
    7.2. Key Findings / Developments
    7.3. Market Value Forecast, by Indication, 2017-2031
        7.3.1. Hypercholesterolemia
        7.3.2. Coronary Artery Disease
        7.3.3. High Triglycerides
    7.4. Market Attractiveness, by Indication
8. Global Lipid-lowering Drugs Market Analysis and Forecast, by Distribution Channel
    8.1. Introduction & Definition
    8.2. Key Findings / Developments
    8.3. Market Value Forecast, by Distribution Channel, 2017-2031
        8.3.1. Hospital Pharmacies
        8.3.2. Retail Pharmacies
        8.3.3. Online Pharmacies
    8.4. Market Attractiveness, by Distribution Channel
9. Global Lipid-lowering Drugs Market Analysis and Forecast, by Region
    9.1. Key Findings
    9.2. Market Value Forecast, by Region
        9.2.1. North America
        9.2.2. Europe
        9.2.3. Asia Pacific
        9.2.4. Latin America
        9.2.5. Middle East & Africa
    9.3. Market Attractiveness, by Country/Region
10. North America Lipid-lowering Drugs Market Analysis and Forecast
    10.1. Introduction
        10.1.1. Key Findings
    10.2. Market Value Forecast, by Drug Class, 2017-2031
        10.2.1. Statins & Combination
        10.2.2. PCSK9 Inhibitors
        10.2.3. Bile Acid Sequestrants
        10.2.4. Fibrates
        10.2.5. Cholesterol Absorption Inhibitors
        10.2.6. Others
    10.3. Market Value Forecast, by Indication, 2017-2031
        10.3.1. Hypercholesterolemia
        10.3.2. Coronary Artery Disease
        10.3.3. High Triglycerides
    10.4. Market Value Forecast, by Distribution Channel, 2017-2031
        10.4.1. Hospital Pharmacies
        10.4.2. Retail Pharmacies
        10.4.3. Online Pharmacies
    10.5. Market Value Forecast, by Country, 2017-2031
        10.5.1. U.S.
        10.5.2. Canada
    10.6. Market Attractiveness Analysis
        10.6.1. By Drug Class
        10.6.2. By Indication
        10.6.3. By Distribution Channel
        10.6.4. By Country
11. Europe Lipid-lowering Drugs Market Analysis and Forecast
    11.1. Introduction
        11.1.1. Key Findings
    11.2. Market Value Forecast, by Drug Class, 2017-2031
        11.2.1. Statins & Combination
        11.2.2. PCSK9 Inhibitors
        11.2.3. Bile Acid Sequestrants
        11.2.4. Fibrates
        11.2.5. Cholesterol Absorption Inhibitors
        11.2.6. Others
    11.3. Market Value Forecast, by Indication, 2017-2031
        11.3.1. Hypercholesterolemia
        11.3.2. Coronary Artery Disease
        11.3.3. High Triglycerides
    11.4. Market Value Forecast, by Distribution Channel, 2017-2031
        11.4.1. Hospital Pharmacies
        11.4.2. Retail Pharmacies
        11.4.3. Online Pharmacies
    11.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        11.5.1. Germany
        11.5.2. U.K.
        11.5.3. France
        11.5.4. Spain
        11.5.5. Italy
        11.5.6. Rest of Europe
    11.6. Market Attractiveness Analysis
        11.6.1. By Drug Class
        11.6.2. By Indication
        11.6.3. By Distribution Channel
        11.6.4. By Country/Sub-region
12. Asia Pacific Lipid-lowering Drugs Market Analysis and Forecast
    12.1. Introduction
        12.1.1. Key Findings
    12.2. Market Value Forecast, by Drug Class, 2017-2031
        12.2.1. Statins & Combination
        12.2.2. PCSK9 Inhibitors
        12.2.3. Bile Acid Sequestrants
        12.2.4. Fibrates
        12.2.5. Cholesterol Absorption Inhibitors
        12.2.6. Others
    12.3. Market Value Forecast, by Indication, 2017-2031
        12.3.1. Hypercholesterolemia
        12.3.2. Coronary Artery Disease
        12.3.3. High Triglycerides
    12.4. Market Value Forecast, by Distribution Channel, 2017-2031
        12.4.1. Hospital Pharmacies
        12.4.2. Retail Pharmacies
        12.4.3. Online Pharmacies
    12.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        12.5.1. China
        12.5.2. Japan
        12.5.3. India
        12.5.4. Australia & New Zealand
        12.5.5. Rest of Asia Pacific
    12.6. Market Attractiveness Analysis
        12.6.1. By Drug Class
        12.6.2. By Indication
        12.6.3. By Distribution Channel
        12.6.4. By Country/Sub-region
13. Latin America Lipid-lowering Drugs Market Analysis and Forecast
    13.1. Introduction
        13.1.1. Key Findings
    13.2. Market Value Forecast, by Drug Class, 2017-2031
        13.2.1. Statins & Combination
        13.2.2. PCSK9 Inhibitors
        13.2.3. Bile Acid Sequestrants
        13.2.4. Fibrates
        13.2.5. Cholesterol Absorption Inhibitors
        13.2.6. Others
    13.3. Market Value Forecast, by Indication, 2017-2031
        13.3.1. Hypercholesterolemia
        13.3.2. Coronary Artery Disease
        13.3.3. High Triglycerides
    13.4. Market Value Forecast, by Distribution Channel, 2017-2031
        13.4.1. Hospital Pharmacies
        13.4.2. Retail Pharmacies
        13.4.3. Online Pharmacies
    13.5. Market Value Forecast By Country/Sub-region, 2017-2031
        13.5.1. Brazil
        13.5.2. Mexico
        13.5.3. Rest of Latin America
    13.6. Market Attractiveness Analysis
        13.6.1. By Drug Class
        13.6.2. By Indication
        13.6.3. By Distribution Channel
        13.6.4. By Country/Sub-region
14. Middle East & Africa Lipid-lowering Drugs Market Analysis and Forecast
    14.1. Introduction
        14.1.1. Key Findings
    14.2. Market Value Forecast, by Drug Class, 2017-2031
        14.2.1. Statins & Combination
        14.2.2. PCSK9 Inhibitors
        14.2.3. Bile Acid Sequestrants
        14.2.4. Fibrates
        14.2.5. Cholesterol Absorption Inhibitors
        14.2.6. Others
    14.3. Market Value Forecast, by Indication, 2017-2031
        14.3.1. Hypercholesterolemia
        14.3.2. Coronary Artery Disease
        14.3.3. High Triglycerides
    14.4. Market Value Forecast, by Distribution Channel, 2017-2031
        14.4.1. Hospital Pharmacies
        14.4.2. Retail Pharmacies
        14.4.3. Online Pharmacies
    14.5. Market Value Forecast, by Country/Sub-region, 2017-2031
        14.5.1. GCC Countries
        14.5.2. South Africa
        14.5.3. Rest of Middle East & Africa
    14.6. Market Attractiveness Analysis
        14.6.1. By Drug Class
        14.6.2. By Indication
        14.6.3. By Distribution Channel
        14.6.4. By Country/Sub-region
15. Competition Landscape
    15.1. Market Player – Competition Matrix (By Tier and Size of companies)
    15.2. Market Share/Ranking Analysis By Company (2022)
    15.3. Company Profiles
        15.3.1. Sanofi
            15.3.1.1. Company Overview
            15.3.1.2. Product Portfolio
            15.3.1.3. SWOT Analysis
            15.3.1.4. Strategic Overview
        15.3.2. Pfizer, Inc.
            15.3.2.1. Company Overview
            15.3.2.2. Product Portfolio
            15.3.2.3. SWOT Analysis
            15.3.2.4. Strategic Overview
        15.3.3. GlaxoSmithKline plc
            15.3.3.1. Company Overview
            15.3.3.2. Product Portfolio
            15.3.3.3. SWOT Analysis
            15.3.3.4. Strategic Overview
        15.3.4. Novartis AG
            15.3.4.1. Company Overview
            15.3.4.2. Product Portfolio
            15.3.4.3. SWOT Analysis
            15.3.4.4. Strategic Overview
        15.3.5. Merck & Co., Inc.
            15.3.5.1. Company Overview
            15.3.5.2. Product Portfolio
            15.3.5.3. SWOT Analysis
            15.3.5.4. Strategic Overview
        15.3.6. Amgen Inc.
            15.3.6.1. Company Overview
            15.3.6.2. Product Portfolio
            15.3.6.3. SWOT Analysis
            15.3.6.4. Strategic Overview
        15.3.7. Takeda Pharmaceutical Company Limited
            15.3.7.1. Company Overview
            15.3.7.2. Product Portfolio
            15.3.7.3. SWOT Analysis
            15.3.7.4. Strategic Overview
        15.3.8. Sun Pharmaceutical Industries Ltd.
            15.3.8.1. Company Overview
            15.3.8.2. Product Portfolio
            15.3.8.3. SWOT Analysis
            15.3.8.4. Strategic Overview
        15.3.9. AbbVie, Inc.
            15.3.9.1. Company Overview
            15.3.9.2. Product Portfolio
            15.3.9.3. SWOT Analysis
            15.3.9.4. Strategic Overview
        15.3.10. Viatris (Mylan N.V.)
            15.3.10.1. Company Overview
            15.3.10.2. Product Portfolio
            15.3.10.3. SWOT Analysis
            15.3.10.4. Strategic Overview
        15.3.11. AstraZeneca PLC
            15.3.11.1. Company Overview
            15.3.11.2. Product Portfolio
            15.3.11.3. SWOT Analysis
            15.3.11.4. Strategic Overview
        15.3.12. Dr. Reddy’s Laboratories Ltd.
            15.3.12.1. Company Overview
            15.3.12.2. Product Portfolio
            15.3.12.3. SWOT Analysis
            15.3.12.4. Strategic Overview